The Wall Street Journal reported that Genzyme is "displaying a new willingness" to discuss a possible deal with Sanofi-Aventis.
Sanofi-Aventis extended an $18.5 billion bid earlier this month, although the Cambridge, MA-based biotechnology company's board members rejected the offer because they said it undervalued Genzyme. Media outlets have speculated that the company's drug pipeline offsets any manufacturing issues.
Also, this week, Genzyme executives told investors and analysts that alemtuzumab, its multiple sclerosis treatment, could generate between $3 billion and $3.5 billion in annual sales by 2017. If sales hit $3.5 billion, alemtuzumab would make up 25% of the market for multiple sclerosis treatments at that time.